EGFRvIII peptide

EGFRvIII peptide

Catalog Number:
P004516813LIF
Mfr. No.:
PEPTIDE-EP-040
Price:
$257
  • Size:
    1mg
    Quantity:
    Add to Cart:
      • Overview
        • EGFRvIII derived epitope.
          EGFRvIII peptide is a peptide derived from the fusion junction of epidermal growth factor receptor variant III (EGFRvIII), a variant of EGFR with amino acids 6 273 deleted. This spontaneously occurring alteration is found in a high percentage of primary human brain, breast, lung and ovarian tumours making EGFRvIII an ideal target of immunotherapy in EGFRvIII-expressing tumours. EGFRvIII peptide was identified from a number of candidates as the most immunogenic epitope for major histocompatibility complex I (MHC I) binding to induce tumour specific immune responses. In a glioblastoma mouse brain tumour model EGFRvIII peptide co-administered with the toll-like receptor 5 (TLR5) adjuvant Flagellin B induces an increase in CD8 ?+ ?T cells and a decrease in Treg cells, inducing tumour apoptosis, inhibiting tumour growth and increasing survival.

          Please contact us for availability.

          Please contact us at for specific academic pricing.

      • Properties
        • Categories
          Peptides
          Alternative Name
          PEGFRvIII, Epidermal growth factor receptor variant III peptide
          Molecular Formula
          C48H78N12O16
          Molecular Weight
          1078.57
          Appearance
          Freeze dried solid
          Purity
          >95% by HPLC
          Solubility
          Soluble in water
          Other Properties
          Sequence: H-Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-OH,LEEKKGNYV
          Storage
          Store dry, frozen and in the dark

          * Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.